Logistic regression model of fotemustine toxicity combining independent phase II studies

Raymond, Éric; Haon, C.; Boaziz, C.; Coste, Maylis

doi:10.1002/(sici)1097-0142(19961101)78:9<1980::aid-cncr20>3.0.co;2-t

Cited by 14 publications

(8 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, the frequency of degree III-IV leukopenia and thrombopenia was 21.7 and 41.7%, respectively. These values are in agreement with those obtained during clinical testing of mustophoran for hematological toxicity [11].…”

supporting

confidence: 89%

Influence of Geomagnetic Activity on Mustophoran Hematotoxicity

Ma¹,

Blank²,

Gershanovich³

2005

Dokl Biol Sci

View full text Add to dashboard Cite

supporting

confidence: 89%

Influence of Geomagnetic Activity on Mustophoran Hematotoxicity

Ma¹,

Blank²,

Gershanovich³

2005

Dokl Biol Sci

View full text Add to dashboard Cite

“…No other case of serious toxicity than uncomplicated leuco-and/or thrombocytopenia from NCI-CTC grades 3 and 4 (9%) occurred during the application of these 268 D/F cycles as well as in further 100 D/F applications in patients with recurrent and lomustine pretreated GBM (Fazeny-Dörner et al, 2000). Otherwise, the toxicity of D/F was similar to the previously reported experience with these compounds, thus making the regimen suitable for completely outward administration (Jacquillat et al, 1990a,b;Aamdal et al, 1992;Fazeny-Dörner et al, 2000;Raymond et al, 1996).…”

Section: Discussionsupporting

confidence: 66%

“…Neither advanced age nor a dismal pretherapeutic KPS could explain this adverse event (Grant et al, 1995;Raymond et al, 1996). No other case of serious toxicity than uncomplicated leuco-and/or thrombocytopenia from NCI-CTC grades 3 and 4 (9%) occurred during the application of these 268 D/F cycles as well as in further 100 D/F applications in patients with recurrent and lomustine pretreated GBM (Fazeny-Dörner et al, 2000).…”

Section: Discussionmentioning

confidence: 98%

Survival with dacarbazine and fotemustine in newly diagnosed glioblastoma multiforme

et al. 2003

View full text Add to dashboard Cite

A total of 55 patients with histologically proven glioblastoma multiforme (total gross resection: n ¼ 24, subtotal resection: n ¼ 20, stereotactic biopsy: n ¼ 11) were treated with the combination of dacarbazine (D) (200 mg m À2 ) and fotemustine (F) (100 mg m À2 ) and concomitant radiotherapy (2 Gy day À1 , 5 days per week using limited fields up to 60 Gy) to assess efficacy and toxicity of this regimen. Survival (median survival, 12-, 18-and 24-month survival rates) and time to progression (median time to progression (TTP), 6-month progression-free survival) were analysed by Kaplan -Meier's method. A total of 268 (range 1 -8, median: 5) cycles were administered. Median survival is 14.5+ (range: 0.5 -40+) months, and the 12-, 18-and 24-month survival rates are 58, 29 and 23%, respectively. Median TTP from the start of D/F therapy is 9.5+ (range: 0.5 -33+) months. The 6-month progression-free survival is 54%. Partial remissions were observed in 3.6%. Main toxicity was thrombocytopenia. Five patients were excluded from further D/F application, four patients because of prolonged thrombocytopenia NCI-CTC grades 3 and 4 and one patient because of whole body erythrodermia. One patient died because of septic fever during thrombocytopenia and leukopenia NCI-CTC grade 4 after the first cycle. No other toxicities of NCI-CTC grade 3 or 4 occurred. The treatment is feasible in a complete outpatient setting and the results of the D/F regimen justify further investigations with these compounds.

show abstract

“…It is worth noting that a univariate analysis carried out on 478 patients treated with fotemustine showed that predictive factors for haematological toxicity were age ( > 50 years), type of tumour (brain < melanoma < others), number of metastatic sites ( > 3), location of metastases (nonvisceral) and previous chemotherapy [8].…”

Section: Discussionmentioning

confidence: 99%

Persistent thrombocytopenia during melanoma treatment with fotemustine

Turrisi¹,

Sozzi²,

Marinozzi³

et al. 2006

Melanoma Research

View full text Add to dashboard Cite

Haematological toxicity characterized by delayed and reversible neutropenia and/or thrombocytopenia is an adverse effect observed in 40% of patients receiving fotemustine. We report the case of a 66-year-old man with metastatic malignant melanoma treated with fotemustine as monotherapy. A severe persistent and prolonged thrombocytopenia occurred, so that chemotherapy was discontinued. Bone marrow involvement was excluded. The physician should be aware of this prolonged thrombocytopenia secondary to fotemustine, so that it may be recognized early and not attributed erroneously to tumour evolution. This observation could be substantial for the design of combination regimens with fotemustine and other myelotoxic drugs in pretreated melanoma patients.

show abstract

Logistic regression model of fotemustine toxicity combining independent phase II studies

Abstract: By combining clinical data from independent Phase II trials, the logistic model developed could predict the probability of fotemustine hematologic and hepatic toxicity.

Cited by 14 publications

References 24 publications

Influence of Geomagnetic Activity on Mustophoran Hematotoxicity

Influence of Geomagnetic Activity on Mustophoran Hematotoxicity

Survival with dacarbazine and fotemustine in newly diagnosed glioblastoma multiforme

Persistent thrombocytopenia during melanoma treatment with fotemustine

Contact Info

Product

Resources

About